Merck braces for Keytruda patent loss with $6.7 billion Terns bet

By Siddhi Mahatole March 25 (Reuters) - Merck said on Wednesday it would buy biotech firm Terns Pharma for $6.7 billion, as ...
Fierce Biotech

Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...
BioPharma Dive

Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug

If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low purchase premium — which one analyst described as a "steal" — may leave room for ...

Terns Pharma shares surge on reported $6B acquisition talks with Merck

Merck & Co. is close to an approximately $6 billion all-cash deal to buy U.S. biotech firm Terns Pharmaceuticals as it seeks to boost its drug pipeline ahead of cancer treatment K ...

Merck announces another pricy purchase ahead of Keytruda deadline

Merck headquarters in Rahway, NJ. RAHWAY, N.J. - Merck is spending $6.7 billion to bolster its cancer drug portfolio. That's the purchase price the New Jersey-based pharmaceutical giant will pay to ...
Nasdaq

Can Keytruda Sustain Merck's Growth Through the Rest of 2025?

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...